Paul Hastings LLP, a leading global law firm, announced today that it represented BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a pharmaceutical company that develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, in connection with its underwritten offering of $375,000,000 aggregate principal amount of its 0.75% Senior Subordinated Convertible Notes due 2018 and $375,000,000 aggregate principal amount of its 1.50% Senior Subordinated Convertible Notes due 2020.
BofA Merrill Lynch, Goldman, Sachs & Co., J.P. Morgan and Morgan Stanley acted as joint book-running managers for the offering. Barclays acted as co-manager for the offering.
In connection with the pricing of the offering and the exercise in full of their overallotment option by the underwriters, BioMarin entered into privately-negotiated capped call transactions with Bank of America, N.A., Morgan Stanley & Co. LLC and Barclays Bank PLC in respect of 50% of the principal amount of the notes.
Securities & Capital Markets partner Thomas Pollock led the Paul Hastings team, which also included partners Robert Claassen, Michael Zuppone, Leigh Ryan and Andrew Short and associates Sasha Burstein,Peiyi Zhao, Christy Chen, Aliza Cohen, Daniel Greenwald and Kaethin Prizer.
